Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Overall MarketRank^™

0.13 out of 5 stars

Medical Sector

1843rd out of 2,041 stocks

Pharmaceutical Preparations Industry

729th out of 769 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Sophiris Bio.

0.0 Community Rank

Outperform Votes
Sophiris Bio has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Sophiris Bio has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote “Outperform” if you believe SPHS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Sophiris Bio does not currently pay a dividend.
Dividend Growth
Sophiris Bio does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sophiris Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.50% of the stock of Sophiris Bio is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Sophiris Bio are expected to grow in the coming year, from ($0.34) to ($0.32) per share.

See Top Rated MarketRank™ Stocks Here

Sophiris Bio (OTCMKTS:SPHS) Frequently Asked Questions

What stocks does MarketBeat like better than Sophiris Bio?

Wall Street analysts have given Sophiris Bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sophiris Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sophiris Bio?

Sophiris Bio saw a drop in short interest in April. As of April 15th, there was short interest totaling 3,400 shares, a drop of 55.8% from the March 31st total of 7,700 shares. Based on an average daily volume of 172,000 shares, the short-interest ratio is presently 0.0 days.
View Sophiris Bio's Short Interest.

How were Sophiris Bio's earnings last quarter?

Sophiris Bio, Inc. (OTCMKTS:SPHS) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.08) EPS for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.02.
View Sophiris Bio's earnings history.

How has Sophiris Bio's stock price been impacted by COVID-19?

Sophiris Bio's stock was trading at $0.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SPHS stock has decreased by 90.8% and is now trading at $0.0212.
View which stocks have been most impacted by COVID-19.

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the following people:

Mr. Randall E. Woods, Pres, CEO & Director (Age 69, Pay $537.28k)
Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board
Dr. James Joseph Beesley, Sr. Director of Investor Relations (Age 49)
Mr. Iain R. Mant, Corp. Sec.

Who are some of Sophiris Bio's key competitors?

Some companies that are related to Sophiris Bio include Innovus Pharmaceuticals (INNVD), Capstone Therapeutics (CAPS), Boston Therapeutics (BTHE), VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), Earth Science Tech (ETST), ImmunoCellular Therapeutics (IMUC), Targeted Medical Pharma (TRGM), Melinta Therapeutics (MLNTQ), Cardax (CDXI), W World (WWHC), Aoxing Pharmaceutical (AOXG), Anthera Pharmaceuticals (ANTH), Achaogen (AKAOQ) and Aeolus Pharmaceuticals (AOLS).
View all of SPHS's competitors.

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the OTCMKTS under the ticker symbol "SPHS."

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $0.02.

How much money does Sophiris Bio make?

Sophiris Bio has a market capitalization of $753,660.00.

How many employees does Sophiris Bio have?

Sophiris Bio employs 6 workers across the globe.

What is Sophiris Bio's official website?

The official website for Sophiris Bio is www.sophirisbio.com.

Where are Sophiris Bio's headquarters?

Sophiris Bio is headquartered at 1258 PROSPECT STREET, LA JOLLA CA, 92037.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The company can be reached via phone at 858-777-1760 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Sophiris Bio Stock Forecast, Price & News

Adding

Adding

Adding Sophiris Bio, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Sophiris Bio

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

0.0 Community Rank

Outperform Votes

Underperform Votes

0.0 Dividend Strength

Dividend Yield

Dividend Growth